[8-K] Zura Bio Limited Reports Material Event

Rhea-AI Filing Summary

Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.

The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.

Positive

• Press release furnished as Exhibit 99.1, ensuring public distribution of the company's second quarter 2025 results
• Disclosure of emerging growth company status, which is explicitly indicated in the filing

Negative

• No financial figures or tables included in the 8-K text; readers must open Exhibit 99.1 for numeric results
• Item 2.02 information is furnished, not "filed", which affects legal incorporation into future filings

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished as an exhibit; no material new financial detail in the Form 8-K itself.

The company furnished a press release reporting quarterly financial results but included no numeric metrics within the 8-K text. As a result, this filing serves primarily as a vehicle to distribute the press release and does not on its own change the financial record. Investors should consult Exhibit 99.1 for the actual figures; until those figures are reviewed, the 8-K is informational and not a material standalone disclosure.

Corporate Governance Expert

TL;DR: Governance disclosure is procedural—the registrant furnished earnings information and explicitly noted it is not being "filed" under the Exchange Act.

The Form 8-K follows standard practice of furnishing a press release under Item 2.02 and listing it as Exhibit 99.1. The statement that the Item 2.02 content is not "filed" is important for legal incorporation considerations. The filing confirms the company’s emerging growth company status, which may affect reporting transitions, but otherwise contains no governance actions or executive changes.

false 0001855644 0001855644 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 14, 2025

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40598		98-1725736
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

(Address of principal executive offices,

including zip code)

(702) 825-9872

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share		ZURA		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Zura Bio Limited (“ZURA”, the “Company”) issued a press release announcing its second quarter 2025 financial results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZURA BIO LIMITED
Date: August 14, 2025	By:	/s/ Kim Davis
		Kim Davis
		Chief Operating Officer, Chief Legal Officer and Corporate Secretary

FAQ

What did Zura Bio (ZURA) disclose in this Form 8-K?

ZURA furnished a press release announcing its second quarter 2025 financial results, included as Exhibit 99.1.

Is the Item 2.02 information in the 8-K considered "filed"?

No. The company states the Item 2.02 information is furnished and should not be deemed "filed" under the Exchange Act.

Where can I find the actual financial results referenced by ZURA?

The financial results are in the press release attached as Exhibit 99.1 to the Form 8-K.

Did the 8-K include financial statements or tables?

No. The filing contains no financial statements or numeric tables; only the press release exhibit is provided.

Does Zura Bio identify as an emerging growth company in the filing?

Yes, the registrant indicated it is an emerging growth company.